The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A microfluidic hepatic coculture platform for cell-based drug metabolism studies
Open accessAbstract
Within the global pharmaceutical and biotech industries, there is significant interest in identifying in vitro screening systems that are more human-relevant—i.e., that offer greater utility in predicting subcellular and cellular physiological responses in humans in vivo—and that thereby allow investigators to reduce the incidence of costly late-stage failures during pharmaceutical clinical trials, as well as to reduce the use of animals in drug testing. Currently incumbent in vitro screening methods, such as culturing human hepatocytes in suspension, while useful, are limited by a lack of long term cellular function. In order to address this limitation, we have established an integrated, microfluidic, in vitro platform that combines the patented HμREL® microdevice with a hepatic coculture system. In the present report, we use this platform to study clearance and metabolite generation of a battery of molecular entities. The results show that the flow-based coculture system is capable of clearing, with improved resolution and predictive value, compounds with high, medium, and low clearance values. In addition, when coculture is coupled with flow, higher metabolite production rates are obtained than in static systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
Pang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797
Cited by
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Advances in Microfluidic Materials, Functions, Integration, and Applications
Nge, P. N., Rogers, C. I., & Woolley, A. T. (2013) · Chemical Reviews · doi:10.1021/cr300337x · Cited by 958
Tissue Engineering and Regenerative Medicine: History, Progress, and Challenges
Berthiaume, F., Maguire, T. J., & Yarmush, M. L. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114257 · Cited by 734
Self-citationIn vitro models for liver toxicity testing
Soldatow, V. Y., LeCluyse, E. L., Griffith, L. G., & Rusyn, I. (2013) · Toxicol. Res. · doi:10.1039/c2tx20051a · Cited by 472
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
Organotypic liver culture models: meeting current challenges in toxicity testing
LeCluyse, E. L., Witek, R. P., Andersen, M. E., & Powers, M. J. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.682115 · Cited by 363
The Role of Body-on-a-Chip Devices in Drug and Toxicity Studies
Esch, M. B., King, T. L., & Shuler, M. L. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124629 · Cited by 328
Cell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
Yoon No, D., Lee, K.-H., Lee, J., & Lee, S.-H. (2015) · Lab on a Chip · doi:10.1039/c5lc00611b · Cited by 205
Competency of different cell models to predict human hepatotoxic drugs
Gómez-Lechón, M. J., Tolosa, L., Conde, I., & Donato, M. T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967680 · Cited by 199
Prantil-Baun, R., Novak, R., Das, D., Somayaji, M. R., Przekwas, A., & Ingber, D. E. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104748 · Cited by 176
Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“Yet, even in 2D monolayers directly exposed to flowing fluid, Novik et al.(148) showed that flow-based cocultures of PHHs and endothelial cells were able to better predict in vivo drug clearance and produce drug Figure 10.”
BackgroundInfluentialFowler, S., Chen, W. L. K., Duignan, D. B., Gupta, A., Hariparsad, N., Kenny, J. R., Lai, W. G., Liras, J., Phillips, J. A., & Gan, J. (2020) · Lab on a Chip · doi:10.1039/c9lc00857h · Cited by 109
Prot, J. M., Maciel, L., Bricks, T., Merlier, F., Cotton, J., Paullier, P., Bois, F. Y., & Leclerc, E. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25232 · Cited by 90
Engineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
“to PHH/NPC co-cultures [46].”
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
“Additionally, an environment that reflects both the in vivo organ scaffolds (such as extracellular matrix) and mechanical signals (like fluid flow) may drastically improve cited models [136,137].”
BackgroundZhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury
Lin, C., & Khetani, S. R. (2016) · BioMed Research International · doi:10.1155/2016/1829148 · Cited by 66
Recent advances in models of immune-mediated drug-induced liver injury
Tasnim, F., Huang, X., Lee, C. Z. W., Ginhoux, F., & Yu, H. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.605392 · Cited by 32
Metadata
- Authors
- Novik, E., Maguire, T. J., Chao, P., Cheng, K. C., & Yarmush, M. L.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 79
- Issue
- 7
- Pages
- 1036-1044
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2159982080
- Cited by
- 212
- References
- 2
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.